A one dose experimental cholera vaccine

FEMS Immunology and Medical Microbiology

Volumn 66, Issue 1, 2012, Pages 98-115

  Muse, Meghan ^a   Grandjean, Cyrille ^b,c   Wade, Terri K ^d   Wade, William F ^d  

^a DARTMOUTH COLLEGE   (United States)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c Faculté des Sciences et Techniques   (France)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cholera vaccine; Colonization factor; LPS; Vibrio cholerae

Indexed keywords

ADJUVANT; ANTIGEN; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; CHOLERA VACCINE; IMMUNOGLOBULIN G; INABA LIPOPOLYSACCHARIDE EL TOR; PHOSPHORYL LIPID A; PROTEIN CBP A; PROTEIN TCPA; PROTEIN TCPF; RIBI; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM PILUS; CONTROLLED STUDY; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIBRIO CHOLERAE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CHOLERA; CHOLERA VACCINES; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; VACCINATION; VIBRIO CHOLERAE;

EID: 84866177718     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2012.00993.x     Document Type: Article

References (74)

1. Acevedo R, Callico A, del Campo J et al. (2009) Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. Methods 49: 309-315.
2. Angelichio MJ, Spector J, Waldor MK & Camilli A (1999) Vibrio cholerae intestinal population dynamics in the suckling mouse model of infection. Infect Immun 67: 3733-3739.
3. Anonymous (2010) Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 85: 117-128.
4. Asaduzzaman M, Ryan ET, John M, Hang L, Khan AI, Faruque AS, Taylor RK, Calderwood SB & Qadri F (2004) The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139. Infect Immun 72: 4448-4454.
5. Attridge SR, Wallerström G, Qadri F & Svennerholm AM (2004) Detection of antibodies to toxin-coregulated pili in sera from cholera patients. Infect Immun 72: 1824-1827.
6. Bellamy JE, Knop J, Steele EJ, Chaicumpa W & Rowley D (1975) Antibody cross-linking as a factor in immunity to cholera in infant mice. J Infect Dis 132: 181-188.
7. Bhowmick R, Ghosal A, Das B, Koley H, Saha DR, Ganguly S, Nandy RK, Bhadra RK & Chatterjee NS (2008) Intestinal adherence of Vibrio cholerae involves a coordinated interaction between colonization factor GbpA and mucin. Infect Immun 76: 4968-4977.
8. Bishop AL, Schild S, Patimalla B, Klein B & Camilli A (2010) Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility. Infect Immun 78: 4402-4420.
9. Boutonnier A, Dassy B, Dumenil R, Guenole A, Ratsitorahina M, Migliani R & Fournier JM (2003) A simple and convenient microtiter plate assay for the detection of bactericidal antibodies to Vibrio cholerae O1 and Vibrio cholerae O139. J Microbiol Methods 55: 745-753.
10. Chao DL, Halloran ME & Longini IM Jr (2011) Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. P Natl Acad Sci USA 108: 7081-7085.
11. Chernyak A, Kondo S, Wade TK, Meeks MD, Alzari PM, Fournier JM, Taylor RK, Kovac P & Wade WF (2002) Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier. J Infect Dis 185: 950-962.
12. Chitnis DS, Sharma KD & Kamat RS (1982) Role of somatic antigen of Vibrio cholerae in adhesion to intestinal mucosa. J Med Microbiol 15: 53-61.
13. Chowdhury MI, Sheikh A & Qadri F (2009) Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009. Expert Rev Vaccines 8: 1643-1652.
14. Clemens JD, Harris JR, Sack DA et al. (1988) Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J Infect Dis 158: 60-69.
15. Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, Shlomchik MJ, Herzenberg LA, Herzenberg LA & Vogel SN (2009) Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. P Natl Acad Sci USA 106: 4343-4348.
16. Cyranoski D (2011) Cholera vaccine plan splits experts. Nature 469: 273-274.
17. Deen JL, von Seidlein L, Sur D, Agtini M, Lucas ME, Lopez AL, Kim DR, Ali M & Clemens JD (2008) The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis 2: e173.
18. Enserink M (2010) Public health. No vaccines in the time of cholera. Science 329: 1462-1463.
19. Eubanks ER, Guentzel MN & Berry LJ (1977) Evaluation of surface components of Vibrio cholerae as protective immunogens. Infect Immun 15: 533-538.
20. Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI & Holmgren J (1985) Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 151: 236-242.
21. Graves PM, Deeks JJ, Demicheli V & Jefferson T (2010) Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected). Cochrane Database Syst Rev 4: CD000974.
22. Griffin DO, Holodick NE & Rothstein TL (2011) Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70J Exp Med 208: 67-80.
23. Hall RH, Losonsky G, Silveira AP, Taylor RK, Mekalanos JJ, Witham ND & Levine MM (1991) Immunogenicity of Vibrio cholerae O1 toxin-coregulated pili in experimental and clinical cholera. Infect Immun 59: 2508-2512.
24. Harris AM, Bhuiyan MS, Chowdhury F et al. (2009) Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun 77: 3850-3856.
25. Hawkes N (2012) Haiti launches vaccination campaign against cholera after much debate. BMJ 344: e2748.
26. Ivers LC, Farmer P, Almazor CP & Leandre F (2010) Five complementary interventions to slow cholera: Haiti. Lancet 376: 2048-2051.
27. Iwanaga M & Yamamoto K (1985) New medium for the production of cholera toxin by Vibrio cholerae O1 biotype El Tor. J Clin Microbiol 22: 405-408.
28. Iwanaga M, Yamamoto K, Higa N, Ichinose Y, Nakasone N & Tanabe M (1986) Culture conditions for stimulating cholera toxin production by Vibrio cholerae O1 El Tor. Microbiol Immunol 30: 1075-1083.
29. Kirn TJ & Taylor RK (2005) TcpF is a soluble colonization factor and protective antigen secreted by El Tor and classical O1 and O139 Vibrio cholerae serogroups. Infect Immun 73: 4461-4470.
30. Kirn TJ, Jude BA & Taylor RK (2005) A colonization factor links Vibrio cholerae environmental survival and human infection. Nature 438: 863-866.
31. Kundu J, Mazumder R, Srivastava R & Srivastava BS (2009) Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge. FEMS Immunol Med Microbiol 56: 179-178.
32. Lanning D, Zhu X, Zhai SK & Knight KL (2000) Development of the antibody repertoire in rabbit: gut-associated lymphoid tissue, microbes, and selection. Immunol Rev 175: 214-228.
33. Leung DT, Rahman MA, Mohasin M et al. (2011) A comparison of memory B cell, antibody secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh. Clin Vaccine Immunol 18: 1317-1325.
34. Lombardo MJ, Michalski J, Martinez-Wilson H, Morin C, Hilton T, Osorio CG, Nataro JP, Tacket CO, Camilli A & Kaper JB (2007) An in vivo expression technology screen for Vibrio cholerae genes expressed in human volunteers. P Natl Acad Sci USA 104: 18229-18234.
35. Lopez-Gigosos RM, Plaza E, Diez-Diaz RM & Calvo MJ (2011) Vaccination strategies to combat an infectious globe: oral cholera vaccines. J Glob Infect Dis 3: 56-62.
36. Mage RG, Sehgal D, Schiaffella E & Anderson AO (1999) Gene-conversion in rabbit B-cell ontogeny and during immune responses in splenic germinal centers. Vet Immunol Immunopathol 72: 7-15.
37. Mahalanabis D, Lopez AL, Sur D et al. (2008) A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS ONE 3: e2323.
38. Meeks MD, Saksena R, Ma X, Wade TK, Taylor RK, Kovac P & Wade WF (2004) Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies. Infect Immun 72: 4090-4101.
39. Megli CJ, Yuen AS, Kolappan S, Richardson MR, Dharmasena MN, Krebs SJ, Taylor RK & Craig L (2011) Crystal structure of the Vibrio cholerae colonization factor TcpF and identification of a functional immunogenic site. J Mol Biol 409: 146-158.
40. Mehr R, Edelman H, Sehgal D & Mage R (2004) Analysis of mutational lineage trees from sites of primary and secondary Ig gene diversification in rabbits and chicken. J Immunol 172: 4790-4796.
41. Mukhopadhyay AK, Garg S, Saha PK, Takeda Y, Bhattacharya SK & Nair GB (1996) Comparative analysis of factors promoting optimal production of cholera toxin by Vibrio cholerae O1 (classical & E1Tor biotypes) & O139. Indian J Med Res 104: 129-133.
42. Mukhopadhyay S, Nandi B & Ghose AC (2000) Antibodies (IgG) to lipopolysaccharide of Vibrio cholerae O1 mediate protection through inhibition of intestinal adherence and colonisation in a mouse model. FEMS Microbiol Lett 185: 29-35.
43. Nielsen AT, Dolganov NA, Rasmussen T, Otto G, Miller MC, Felt SA, Torreilles S & Schoolnik GK (2010) A bistable switch and anatomical site control Vibrio cholerae virulence gene expression in the intestine. PLoS Pathog 6: e1001102.
44. Nygren E, Holmgren J & Attridge SR (2008) Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae. Vaccine 26: 6784-6790.
45. Oliver AM, Martin F, Gartland GL, Carter RH & Kearney JF (1997) Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur J Immunol 27: 2366-2374.
46. Osek J, Jonson G, Svennerholm AM & Holmgren J (1994) Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera. Infect Immun 62: 2901-2907.
47. Osorio CG, Crawford JA, Michalski J, Martinez-Wilson H, Kaper JB & Camilli A (2005) Second-generation recombination-based in vivo expression technology for large-scale screening for Vibrio cholerae genes induced during infection of the mouse small intestine. Infect Immun 73: 972-980.
48. Perez JL, Acevedo R, Callico A et al. (2009) A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice. Vaccine 27: 205-212.
49. Provenzano D, Kovac P & Wade WF (2006) The ABCs (antibody, B cells, and carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine. Microbiol Immunol 50: 899-927.
50. Rollenhagen JE, Kalsy A, Cerda F, John M, Harris JB, Larocque RC, Qadri F, Calderwood SB, Taylor RK & Ryan ET (2006) Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice. Infect Immun 74: 5834-5839.
51. Sack DA, Clemens JD, Huda S et al. (1991) Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J Infect Dis 164: 407-411.
52. Saha D, LaRocque RC, Khan AI, Harris JB, Begum YA, Akramuzzaman SM, Faruque AS, Ryan ET, Qadri F & Calderwood SB (2004) Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J Infect Dis 189: 2318-2322.
53. Saha A, Chowdhury MI, Khanam F et al. (2011) Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 29: 8285-8292.
54. Sánchez J, Medina G, Buhse T, Holmgren J & Soberón-Chavez G (2004) Expression of cholera toxin under non-AKI conditions in Vibrio cholerae El Tor induced by increasing the exposed surface of cultures. J Bacteriol 186: 1355-1361.
55. Shahiwala A & Amiji MM (2008) Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice. J Drug Target 16: 302-310.
56. Spencer J, Finn T, Pulford KA, Mason DY & Isaacson PG (1985) The human gut contains a novel population of B lymphocytes which resemble marginal zone cells. Clin Exp Immunol 62: 607-612.
57. Sun DX, Mekalanos JJ & Taylor RK (1990) Antibodies directed against the toxin-coregulated pilus isolated from Vibrio cholerae provide protection in the infant mouse experimental cholera model. J Infect Dis 161: 1231-1236.
58. Sun DX, Seyer JM, Kovari I, Sumrada RA & Taylor RK (1991) Localization of protective epitopes within the pilin subunit of the Vibrio cholerae toxin-coregulated pilus. Infect Immun 59: 114-118.
59. Svennerholm AM (1975) Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity. Int Arch Allergy Appl Immunol 49: 434-452.
60. Svennerholm AM, Hanson LA, Holmgren J, Lindblad BS, Nilsson B & Quereshi F (1980) Different secretory immunoglobulin A antibody responses to cholera vaccination in Swedish and Pakistani women. Infect Immun 30: 7-30.
61. Tacket CO, Cohen MB, Wasserman SS et al. (1999) Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun 67: 6341-6345.
62. Taylor RK, Kirn TJ, Meeks MD, Wade TK & Wade WF (2004) A Vibrio cholerae classical TcpA amino acid sequence induces protective antibody that binds an area hypothesized to be important for toxin-coregulated pilus structure. Infect Immun 72: 6050-6060.
63. Trach DD, Cam PD, Ke NT et al. (2002) Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull World Health Organ 80: 2-8.
64. Vijayashree S, Nayak N, Panigrahi D & Sehgal S (2003) Role of cell surface antigens of Vibrio cholerae 01 and non 01 serovars in intestinal adhesion. Indian J Pathol Microbiol 46: 259-260.
65. Wade WF (2011) Is a universal, one dose cholera vaccine possible? Open Vaccine J 4: 18-30.
66. Wade TK & Wade WF (2008) Variable gene family usage of protective and non-protective anti-Vibrio cholerae O1 LPS antibody heavy chains. Microbiol Immunol 52: 611-620.
67. Wade TK, Saksena R, Shiloach J, Kovac P & Wade WF (2006) Immunogenicity of synthetic saccharide fragments of Vibrio cholerae O1 (Ogawa and Inaba) bound to Exotoxin A. FEMS Immunol Med Microbiol 48: 237-251.
68. Wasserman SS, Losonsky GA, Noriega F, Tacket CO, Castaneda E & Levine MM (1994) Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine 12: 1000-1003.
69. Weill JC, Weller S & Reynaud CA (2009) Human marginal zone B cells. Annu Rev Immunol 27: 267-285.
70. Weller S, Faili A, Aoufouchi S, Gueranger Q, Braun M, Reynaud CA & Weill JC (2003) Hypermutation in human B cells in vivo and in vitro. Ann NY Acad Sci 987: 158-165.
71. WHO (2011) Cholera country profile: Haiti WHO Global Task Force on Cholera Control 1-2. WHO, Geneva.
72. Wong E, Vaaje-Kolstad G, Ghosh A, Hurtado-Guerrero R, Konarev PV, Ibrahim AF, Svergun DI, Eijsink VG, Chatterjee NS & van Aalten DM (2012) The Vibrio cholerae colonization factor GbpA possesses a modular structure that governs binding to different host surfaces. PLoS Pathog 8: e1002373.
73. Wu JY, Wade WF & Taylor RK (2001) Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect Immun 69: 7695-7702.
74. Zuckerman JN, Rombo L & Fisch A (2007) The true burden and risk of cholera: implications for prevention and control. Lancet Infect Dis 7: 521-530.